Christopher R. Fenimore

CIK: 0001697422

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (14.3%)

Derivative conversions

Awards (A)2 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)4 (57.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

REGN

REGENERON PHARMACEUTICALS, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

REGN
REGENERON PHARMACEUTICALS, INC.
Aug 18, 2026
Tax Payment(F)
Direct
4.6K shares at avg. $813.47$3.7M
REGN
REGENERON PHARMACEUTICALS, INC.
Aug 18, 2026
Exercise(M)
Direct
6.3K shares at avg. $381.92$2.4M
REGN
REGENERON PHARMACEUTICALS, INC.
Dec 8, 2025
Tax Payment(F)
Direct
992 shares at avg. $712.94$707K
REGN
REGENERON PHARMACEUTICALS, INC.
Dec 5, 2025
Award(A)
Direct
3K shares-
REGN
REGENERON PHARMACEUTICALS, INC.
Dec 16, 2024
Tax Payment(F)
Direct
491 shares at avg. $730.81$359K
REGN
REGENERON PHARMACEUTICALS, INC.
Dec 9, 2024
Tax Payment(F)
Direct
1.1K shares at avg. $787.00$897K
REGN
REGENERON PHARMACEUTICALS, INC.
Dec 6, 2024
Award(A)
Direct
2.6K shares-

		Type	Shares	Price		Ownership
Aug 18, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Tax Payment(F)	4,599	$813.47	$3,741,149	Direct
Aug 18, 2026	REGN REGENERON PHARMACEUTICALS, INC.	Exercise(M)	6,283	$381.92	$2,399,603	Direct
Dec 8, 2025	REGN REGENERON PHARMACEUTICALS, INC.	Tax Payment(F)	992	$712.94	$707,236	Direct
Dec 5, 2025	REGN REGENERON PHARMACEUTICALS, INC.	Award(A)	3,027	-	-	Direct
Dec 16, 2024	REGN REGENERON PHARMACEUTICALS, INC.	Tax Payment(F)	491	$730.81	$358,828	Direct
Dec 9, 2024	REGN REGENERON PHARMACEUTICALS, INC.	Tax Payment(F)	1,140	$787.00	$897,180	Direct
Dec 6, 2024	REGN REGENERON PHARMACEUTICALS, INC.	Award(A)	2,591	-	$0	Direct

1-7 of 7 transactions

About Fenimore Christopher R.

Fenimore Christopher R. (SEC CIK 0001697422) files insider reports with the SEC as EVP Finance CFO of REGENERON PHARMACEUTICALS, INC. (REGN).

Signal8 holds 4 ownership filings by Fenimore Christopher R., all Form 4s, filed between Dec 10, 2024 and Aug 20, 2026. Those filings report 7 transactions, from Dec 6, 2024 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Fenimore Christopher R.'s filings is in TARRYTOWN, NY.

Recent filings by Fenimore Christopher R.

Aug 18, 2026: Tax withholding of REGN shares (Form 4, code F).
Aug 18, 2026: Option exercise of REGN shares (Form 4, code M).
Dec 8, 2025: Tax withholding of REGN shares (Form 4, code F).
Dec 5, 2025: Grant or award of REGN shares (Form 4, code A).
Dec 16, 2024: Tax withholding of REGN shares (Form 4, code F).

Other insiders filing for REGENERON PHARMACEUTICALS, INC. (REGN)

Guarini Kathryn, Director
BROWN MICHAEL S, Director
McCourt Marion, EVP Commercial
MURPHY ANDREW J, Co-Chief Scientific Officer
LAROSA JOSEPH J, EVP General Counsel and Secret
Zoghbi Huda Y, Director

How to read Form 4 transaction codes